Building upon Qpex's validated beta-lactamase inhibitor technology that led to FDA approval of the first member of this new drug class, ORAvance is an oral combination product that delivers QPX7728 by the oral route of administration, and has the potential to be a new effective treatment option that overcomes bacterial resistance mechanisms in settings where IV therapy is not possible or desirable.
The Phase 1, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics in healthy adult participants.
The study is being conducted as part of its partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant secretary for Preparedness and Response at the US Department of Health and Human Services.
Qpex Biopharma has three development programs focused on the treatment of drug-resistant pathogens that the Center for Disease Control considers serious or urgent antimicrobial resistance threats, including Acinetobacter spp., Pseudomonas aeruginosa, and Enterobacteriaceae.
The World Health Organization has also prioritized development of new treatments for these pathogens.
Qpex's portfolio comprehensively addresses patient needs in both the inpatient and outpatient settings.
Two of the products use QPX7728, an ultra-broad-spectrum beta-lactamase inhibitor that restores the potency of beta-lactam antibiotics in vitro and in vivo.
The development of the products in Qpex's portfolio is funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under OTA number HHSO100201600026C.
To date, BARDA has provided USD67 m and technical support. If all options are awarded, the agreement would provide up to USD 132m in support for the development of a portfolio of new antibiotics to fight drug-resistant gram-negative infections.
Qpex Biopharma is a resistance-focused infectious disease company on a mission to make both a dramatic and sustainable improvement in patient care across both inpatient and outpatient settings.
Advancing a robust portfolio of best-in-class clinical candidates, the company's lead program is based on QPX7728, a novel ultra-broad-spectrum beta-lactamase inhibitor discovered by Qpex scientists.
The company currently has a partnership with Biomedical Advanced Research and Development Authority (BARDA) focused on advancing novel antibiotics and a multi-product collaboration with Brii Biosciences for the development and commercialization of three of its products in greater China.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT